Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients

Summary

The purpose of this Medical Access Program (also referred to as an Expanded Access Program in the USA) is to provide access to Dato-DXd for eligible patients with previously treated advanced or metastatic EGFR mutated non-small cell lung cancer (NSCLC) who, in their treating physician's opinion, have an unmet clinical need, are unlikely to obtain optimal benefit from currently approved and commercially available drugs, and who cannot enter a suitable clinical trial.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications